Therapeutisches Management bei der Akromegalie
- Resource Type
- Original Paper
- Authors
- Metzner, Cornelia; Hadziselimovic, Senad; Grafe, Ingo; Nawroth, Peter; Kasperk, Christian
- Source
- Medizinische Klinik: Zeitschrift für Innere Medizin in Klinik und Praxis Offizielles Organ der Deutschen Gesellschaft für Innere Medizin (DGIM) Journal for Internal Medicine in Hospital and Private Practice. 101(1):15-23
- Subject
- Akromegalie
Therapie
Somatostatinanaloga
Dopaminagonisten
GH-Rezeptor-Antagonist
Acromegaly
Treatment
Somatostatin analogs
Dopamine agonists
GH receptor antagonist
- Language
- German
- ISSN
- 0723-5003
1615-6722
Abstract: Background:: Only 60% of the patients with acromegaly are biochemically cured (growth hormone [GH] nadir < 1.0 µg/l after an oral glucose load, normalized age- and gender-matched insulin-like growth factor-1 [IGF-1] levels) after transsphenoidal surgery of the pituitary gland. In the absence of a remission there are effective pharmacological treatment regimens available which are able to lower GH and IGF-1 serum levels.Therapeutic Strategies:: Somatostatin analogs, a GH receptor antagonist and dopamine agonists have been shown to alleviate the comorbid features and to normalize GH and IGF-1 levels.Case Reports:: In this overview six case reports are presented to highlight the current pharmacological treatment options and to propose an algorithm for the clinical routine in patients with persisting acromegaly.Conclusion:: Transsphenoidal surgery is the treatment of choice for the initial management of acromegaly. In the absence of a remission there are effective pharmacological treatment regimens available among which somatosatin analogs are recommended as the first-line treatment.